Repurposed cancer drug shows promise for Parkinson’s

News

Author: Simge Eva DoganPublished: 5 December 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

cancer drug Parkinson's

Researchers at the Oxford Parkinson’s Disease Centre, UK, have repurposed an experimental cancer drug – called tasquinimod – as a potential treatment for Parkinson’s.

The study – funded by Parkinson’s UK and published in science journal ‘Cell Stem Cell’ – has been tested on a total of 10 patients so far.

As part of the research, the study grew brain cells from donated skin cell samples of people living with a rare genetic form of Parkinson’s – this process was then repeated on people with a common non-genetic form of the condition. Researchers found that tasquinimod can block HDAC4, a protein that causes Parkinson’s genes to become inactive.

Professor Richard Wade-Martins, co-lead author of the study, said: “We think that switching off these genes in brain cells may play a vital role in the cell damage and death that occurs in Parkinson’s.”

To read more on this topic click here.

For more information on the latest Parkinson’s research please visit the EPDA website.


Read more:

Research survey assesses impact of holidays on Parkinson’s symptoms

World’s largest Parkinson’s study seeks 10,000 participants

Go Back

Share this story

Comments


Related articles


Europe

Walk with Copenhagen

Join the Danish Parkinson Association for their annual event

READ MORE
1 hour more lead

Resources & Tools

A series of 12 videos to offer practical Parkinson’s advice

What would you do if you had one hour more of ‘on time’ each day?

READ MORE
MJFF Third Thursday webinar YOPD

Resources & Tools

Young-onset Parkinson’s disease: the challenges and treatment options

Register for this free, hour-long webinar

READ MORE